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Abstract
Merkel cell polyomavirus (MCV), a previously unrecognized component of the human viral skin flora, was discovered as a
mutated and clonally-integrated virus inserted into Merkel cell carcinoma (MCC) genomes. We reconstructed a replicating
MCV clone (MCV-HF), and then mutated viral sites required for replication or interaction with cellular proteins to examine
replication efficiency and viral gene expression. Three days after MCV-HF transfection into 293 cells, although replication is
not robust, encapsidated viral DNA and protein can be readily isolated by density gradient centrifugation and typical
,40 nm diameter polyomavirus virions are identified by electron microscopy. The virus has an orderly gene expression
cascade during replication in which large T (LT) and 57kT proteins are first expressed by day 2, followed by expression of
small T (sT) and VP1 proteins. VP1 and sT proteins are not detected, and spliced 57kT is markedly diminished, in the
replication-defective virus suggesting that early gene splicing and late gene transcription may be dependent on viral DNA
replication. MCV replication and encapsidation is increased by overexpression of MCV sT, consistent with sT being a limiting
factor during virus replication. Mutation of the MCV LT vacuolar sorting protein hVam6p (Vps39) binding site also enhances
MCV replication while exogenous hVam6p overexpression reduces MCV virion production by .90%. Although MCV-HF
generates encapsidated wild-type MCV virions, we did not find conditions for persistent transmission to recipient cell lines
suggesting that MCV has a highly restricted tropism. These studies identify and highlight the role of polyomavirus DNA
replication in viral gene expression and show that viral sT and cellular hVam6p are important factors regulating MCV
replication. MCV-HF is a molecular clone that can be readily manipulated to investigate factors affecting MCV replication.
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Introduction
Merkel cell polyomavirus (MCV) was identified by digital
transcriptome subtraction from Merkel cell carcinoma (MCC), a
rare but aggressive human skin cancer [1,2]. MCV is a double-
stranded DNA virus belonging to the Polyomaviridae family, members
of which share conserved early, late, and regulatory regions. The
polyomavirus early viral tumor (T) antigens play key roles in viral
genome replication as well as tumorigenesis. Large T (LT) antigen-
encoded helicase activity, for example, unwinds the viral replication
origin [3,4] and enhances the polyomavirus late promoter leading to
an early-to-late switch in gene expression. For murine polyoma-
virus, this switch has been shown to depend on LT-initiated viral
DNA replication [5]. The late region encodes viral capsid proteins
(VP1 and VP2) that self-assemble into virus-like particles (VLP)
when expressed in cells [6,7,8,9,10]. MCV VLP have been used to
infect cells and can be used in neutralization experiments [6] but
replication of full MCV genome has not been described. The
concerted regulation and interaction of both early and late
polyomavirus proteins are necessary to produce viral particles.
Loss of viral replication capacity, or permissivity, is a common
feature of virus-initiated tumors [11,12]. Approximately 80% of
MCC are infected with MCV in which the viral genome is
clonally-integrated into the host tumor cell genome, preventing
viral replication [1,13,14]. MCV obtained from tumors also
possess LT gene mutations that are a central feature of MCV-
driven human tumor formation [13]. LT normally binds a specific
site in the viral replication origin and initiates DNA replication
through its C-terminal helicase domain. Tumor-specific mutations
prevent LT-initiated DNA replication at the integrated genome
thus preventing independent and unlicensed DNA replication
from the viral genome that could lead to catastrophic replication
fork collisions and DNA breakage when multiple virus-initiated
replication forks proceed onto the cellular DNA template [13].
The minimal MCV replication origin has been mapped to a
71 bp fragment in a non-coding region that LT protein binds in
order to initiate viral DNA replication. Among MCV proteins, LT
protein alone is sufficient for this process but MCV small T (sT)
protein acts as an accessory factor that greatly increases the
efficiency of MCV origin firing [3]. We have recently described
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MCV sT as a transforming oncoprotein in MCC that inactivates
the Akt-mTOR pathway protein 4E-BP1 and activates cap-
dependent protein translation in MCV-positive tumors [15]. In
one MCV tumor strain (MCV350), a point mutation in its
replication origin prevents proper assembly of the LT helicase
complex, also rendering the tumor-derived virus nonpermissive
[3]. Additional virus mutations in capsid genes, including in the
MCV350 strain, have been described that are predicted to prevent
virion self-assembly and replication [16]. The sT and the N-
terminal portions of LT, however, are unaffected by tumor-specific
mutations, suggesting that they may play a key role in MCC
tumorigenesis. The importance of viral early gene contributions to
this cancer are shown by knockdown of the common T antigen
exon 1 sequence, which leads to cell cycle arrest and cell death of
MCV-positive MCC cells [17].
More than 50% of the healthy adult population is serologically
positive for MCV antibodies [6,7,18,19] and most adult MCV
infections are asymptomatic [20]. In contrast to MCC tumors, only
very low level MCV genomic DNA is present in healthy tissues,
including skin, peripheral blood mononuclear cells, gastrointestinal
tract [1,21,22], human respiratory tract secretions [23], and other
tissues [21]. Using rolling circle amplification, Schowalter et al. have
recently isolated several encapsidated strains of wild-type MCV
from healthy skin [22]. Nonetheless, the limiting amounts of wild-
type MCV flora present in healthy tissues have been a significant
barrier to isolation of replication-competent MCV.
To search for novel cellular factors binding to MCV early
proteins, we performed tandem-affinity pulldown assays with a
unique region of the MCV LT [24]. An MCV LT domain that is
conserved in both tumor-derived and wild-type MCV strains
interacts with the cytoplasmic vacuolar sorting protein, hVam6p
(also known as Vps39), a component of the HOPS (homotypic
fusion and protein sorting) complex involved in late endosomal
and lysosomal fusion [25]. Coexpression of MCV LT with
hVam6p causes relocalization of hVam6p from the cytoplasm,
where it is normally found, to the nucleus and to perinuclear
bodies. This interaction can be abrogated by a single alanine
substitution at tryptophan 209 (LT.W209A) in the hVam6p
binding domain of LT. No differences in cell viability or cell
cycling have been detected for the wild-type LT and LT.W209A
expression and so the role for this LT interaction remains
unknown. MCV LT antagonizes the ability of hVam6p to induce
lysosomal clustering, raising the possibility that hVam6p might
modulate MCV replication or egress [24].
Development of an MCV molecular clone allows engineering
the viral genome, such as introducing a mutation at the hVam6p
interaction site in LT, to examine effects on virus replication and
assembly. To generate an MCV clone, we aligned MCV genomes
from MCC tumors as well as non-tumor tissues and designed a
consensus MCV molecular genome (MCV-HF). Subsequent to
construction of this consensus clone, the same viral sequence was
identified in several naturally occurring MCV strain obtained from
healthy human skin samples [22], supporting the notion that
MCV-HF is a permissive viral clone.
We show here that the MCV-HF clone is replication competent
and sequentially expresses early and late viral proteins to generate
packaged virions after transfection of the molecular clone DNA into
293 cells. MCV-HF has modest but reproducible replication
capacity in a variety of tissue culture cell lines that is enhanced by
MCV sT coexpression. In contrast, MCV engineered with the
MCV350 origin point mutation is replication-deficient, only
transiently expresses LT protein, has diminished or absent
expression of other early spliced transcript protein forms and does
not express late MCV protein. Overexpression of hVam6p is potent
in inhibiting MCV replication whereas engineering MCV-HF with
the LT.W209Amutation amplifies virus replication suggesting a key
role for this vacuolar sorting protein in MCV virion production.
Results
Design and construction of a consensus MCV genome
At the initiation of this study, no full-length viral genomes from
nontumor sources had been isolated. We originally found 8 of 10
(80%) MCC tumors to be positive for MCV DNA [1]. We
sequenced full-length MCV genomes by PCR-direct sequencing
from 5 of the 8 virus-positive tumors (MCV350, MCV339,
MCV344, MCV349, MCV352), as well as from 1 MCV positive
cell line (MKL-1), which were compared to a single whole virus
sequence (MCV85) obtained from a peripheral blood sample
(Fig. 1A). All tumor-derived sequences have T antigen truncations,
including mutations or short genomic deletions. For some strains,
tumor-derived mutations are also observed in late gene regions, as
reported by A. Zur Hausen’s group [16]. For example, a 200-bp
deletion is present in the VP1 locus of MCC352, generates a
truncated VP1 protein that is likely to lead to incomplete viral
assembly for this strain (Fig. 1A).
To address the issue of polymorphisms between and within
individual cases, we designed a consensus genome (MCV-HF,
GenBank ID: JF813003). This cloned genomic DNA (available
through our website, www.tumorvirology.pitt.edu/mcvtools.html)
is based on the 7 full-length MCV genomes. Compared to these
genomes, the MCV-HF genome is located centrally in the
phylogenetic tree (Fig. 1B), closest to wild-type R17a strain and
has the same nucleotide sequence as the 17b, 18b and 20b strains
identified by Schowalter et al. from human normal skin [22]. The
consensus MCV-HF was synthesized and cloned into a kanamycin
selectable vector (Fig. 1C). An MCV genome variant possessing
the MCV350 mutation in the replication origin (MCV-Rep2) was
generated by site-directed mutagenesis to serve as a negative
control for viral replication [3].
MCV-HF and MCV-Rep2 viral protein expression in 293
cells
MCV-HF or MCV-Rep2 circular genome DNAs were
transfected into 293 cells and viral protein expression was
determined by immunoblotting for LT, 57kT, sT antigen and
VP1 proteins (Fig. 2). The defective replication origin in MCV-
Rep2 genome does not affect initial LT antigen expression,
indicating that this mutation does not directly alter early gene
transcription. LT protein is readily detected 24 hrs after
transfection for both MCV-HF and MCV-Rep2 and equal
amounts of LT expressed by day 2 for both clones. This reveals
that the early promoter regulating LT is intact in both viruses and
similarly active at time points prior to active viral replication and
amplification. Surprisingly, expression of the alternatively spliced
57kT form is reduced with MCV-Rep2 at day 2. This is not due to
differences in detection since both LT and 57kT are determined
on the same blots with the same CM2B4 antibody. LT protein
expression continues over 5 days for the MCV-HF virus. LT
protein levels peak at 48 hrs for MCV-Rep2 and then
subsequently decline. Notably, the spliced 57kT antigen protein
is diminished at all time points for the MCV-Rep2 clone. In
contrast to LT and 57kT, no sT (an alternate spliced form from
the early Tag locus) expression is detected after transfection of
MCV-Rep2, but sT is readily detected by day 3 after transfection
with the replication-competent genome. These findings suggest
that splicing efficiency among early MCV genes may be
dependent on viral genome replication.
Merkel Cell Polyomavirus Molecular Clone
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VP1 structural protein also increases in abundance from day 3
through 5 post MCV-HF transfection (Fig. 2), consistent with a
switch from early to late gene expression to generate spontane-
ously assembling virus particles. VP1 expression, however, is not
detected after MCV-Rep2 transfection. Thus, in 293 cells,
transient transfection of only the wild-type MCV-HF genome
produces both early and late proteins required for virus replication
and assembly. Alternatively-spliced early proteins (sT and 57kT)
are diminished or absent, as is the late VP1 protein, for the MCV-
Rep2 virus despite similar initial levels of LT expression with both
permissive and nonpermissive viruses.
Detection of MCV-HF virus in 293 cells
We next examined virion production in 293 cells transfected
with MCV-HF. At day 4 post MCV-HF transfection, cells were
harvested, lysed, matured overnight and treated with benzonase,
RNase A and Plasmid-safeTM nuclease. Fractions were collected
from an ultracentrifuged OptiprepTM (iodixanol) gradient and
immunoblotted for VP1 protein (Fig. 3A). High molecular weight
aggregates of the ,45 kDa VP1 protein are present in fraction 4
having a 1.24 g/ml buoyant density. A high molecular weight VP1
form (,90 kDa) is also present polyacrylamide gels that may
represent covalently-crosslinked dimeric VP1 protein. VP1 is also
present in the lowest density fractions 9 and 10, that represent
unassembled, free VP1 protein. Fraction 4 contains typical 38–
43 nm diameter polyomavirus particles detected by transmission
electron microscopy with uranyl acetate negative staining (Fig. 3B).
Quantitative real-time PCR for DNA isolated from Optiprep
gradients reveals highest copy numbers of nuclease-resistant DNA
in fraction 4 (Fig. 3C). In contrast, nuclease-resistant MCV
genome is not detected in fractions 9 and 10, consistent with
digestion of unencapsidated DNA. Encapsidated viral DNA
increases up to day 4 after MCV-HF transfection and then
plateaus (representative results are shown in Fig. 3D), correlating
with VP1 protein expression levels. As expected for the
nonreplicating virus, viral DNA is present immediately after
Figure 1. MCV genome. (A) Full-length of MCV genomes identified from 5 MCC tumors (MCV350, MCV339, MCV344, MCV349, MCV352), 1 MCC cell
line (MCVMKL-1) and 1 PBMC sample (MCV85). T antigen ORFs are shown in blue arrows, VP ORFs in pink arrows. Numbers stand for positions in MCV
genome. Black solid boxes indicate genomic deletions in MCV genome. (B) Phylogenetic tree of MCV genomes. The consensus genome (MCV-HF,
JF813003) is located in the center of a tree including MCV350 (EU375803), MCV339 (EU375804), MCV344 (JF812999), MCV349 (JF813000), MCV352
(JF813001), MCVMKL-1 (FJ173815), MCV85 (JF813002) and other MCV sequences obtained from human skin [22] and Kaposi’s sarcoma [40]. (C) The
consensus MCV-HF genome can be linearized at BsrFI site (4,596 nt) and cloned for propagation in E. coli. Sites for mutations engineered into two
MCV-HF genomes (MCV-Rep2 (C/A) and MCV-hVam6p2 (TG/GC)) are shown.
doi:10.1371/journal.pone.0022468.g001
Merkel Cell Polyomavirus Molecular Clone
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MCV-Rep2 transfection but diminishes below the level of
detectability by day 5.
These findings are confirmed by Southern blotting for viral
DNA (Fig. 4). In this experiment, DNA from 293 cells 4 days post-
transfection, with either MCV-HF (lane 1) or MCV-Rep2 (lane 2),
were treated with DpnI to digest unreplicated DNA and with
BamHI to linearize MCV genome. No bands are present for
MCV-Rep2, while a weak 5.4 kb DpnI-resistant band representing
full-length genome is present in extracts from MCV-HF
transfected 293 cells. Significantly, a subgenomic 0.3–2 kb smear
of DpnI-resistant MCV DNA is also present, consistent with a large
fraction replicated MCV DNA being composed of either
abortively-replicated or partially-digested genome fragments.
Optimization of MCV clone replication
To determine whether coexpression of MCV early genes might
enhance MCV replication, 293 cells were stably transduced with
MCV sT, LT or empty vector expression constructs. MCV-HF and
MCV-Rep2 genomes were then transfected into these cells and
MCV virion production was quantitated by real-time PCR. Cells
coexpressing MCV sT generate approximately 5-fold increased
nuclease-protected MCV DNA compared to cells without sT
coexpression (Fig. 5). In contrast, only a small increase in MCV
DNA is present in cells stably expressing LT protein, suggesting that
sT but not LT protein levels are limiting for genome replication
after transfection. Several other cell lines (UISO, 293TT, NIH3T3
and COS7) were also examined, with and without various MCV
gene coexpressions, in an attempt to optimize MCV virion
production (Table 1). None of these conditions led to appreciably
greater MCV virion production compared to 293 cells alone.
hVam6p interaction with MCV LT diminishes MCV
replication
Tandem-affinity pulldown studies have found that MCV LT
binds to hVam6p and relocalizes it from the cytoplasm to the
nucleus, but the biological importance of this interaction is unknown
[24]. A mutant MCV-HF, designated as MCV-hVam6p2, was
engineered to encode a W209A substitution in the LT gene to
prevent hVam6p interaction and to test its role in MCV replication.
As seen in Fig. 5, mutation of the hVam6p-binding site leads to a 4–
6 fold increase in nuclease-resistant virion production compared to
the wild-type MCV-HF virus. Enhanced virion replication is
additive with sT coexpression, suggesting that LT.W209A and sT
coexpression are independent of each other and act at different
stages of replication. Increased virion and subgenomic DNA
production for MCV-hVam6p2 was confirmed by Southern
blotting (Fig. 4, lane 3). The comparable levels of DpnI-sensitive
bands in all lanes on the Southern blot demonstrate that this effect is
unlikely to be due to differences in transfection efficiency.
Immunoblotting for encapsidated VP1 after gradient purification
also reveals markedly increased viral particle production with
MCV-hVam6p2 genome (Fig. 6). In contrast, hVam6p coexpres-
sion inhibits nuclease-resistant, encapsidated DNA production from
MCV-HF to levels comparable to the nonpermissive MCV-Rep2
virus (Fig. 7). The MCV-hVam6p2 clone replication is relatively
resistant to the effects of hVam6p coexpression compared to MCV-
HF but also declines in a dose-dependent fashion. hVam6p
overexpression does not decrease 293 cell viability or alter cell
cycling, nor does it alter transfection efficiency (data not shown).
Since hVam6p is normally a cytoplasmic protein that relocalizes
to nuclear and perinulclear sites when MCV LT is co-expressed,
we sought to determine whether hVam6p might directly inhibit
viral DNA synthesis in the presence of LT (Fig. 8). An in vitro origin
replication assay was performed with either the entire T antigen
gene locus, TAg (expressing LT, 57kT and sT), or the LT cDNA
alone. These plasmids were transfected together with the MCV
origin cloned into the pCR2.1 vector, with or without hVam6p
expression. Southern blotting for the origin plasmid measures T
antigen-initiated DNA replication (DpnI-resistant band) relative to
unreplicated, transfected origin DNA (DpnI-sensitive band) [3].
Figure 2. Coordinated viral gene expression during MCV replication in 293 cells. One microgram of recircularized MCV genomes (wild-
type MCV-HF or replication-defective MCV-Rep2) was transfected into 293 cells. Immunoblotting was performed to examine T antigen expression
over 5 days (indicated by hollow arrows) and VP1 protein (indicated by solid arrow) using CM2B4 (LT, 57kT), CM8E6 (sT) and CM9B2 (VP1) antibodies,
respectively. Alpha-tubulin detection was used as a protein loading control. LT protein is expressed equally at day 2 for both viruses but decreases for
MCV-Rep2 on days 3–5. VP1 increases on days 3–5 only for MCV-HF, corresponding to viral DNA replication (Fig. 3D). Other early proteins are also
diminished (57kT) or absent (sT) in the replication deficient MCV-Rep2.
doi:10.1371/journal.pone.0022468.g002
Merkel Cell Polyomavirus Molecular Clone
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As previously reported [3], the genomic TAg locus (Fig. 8 , lane
3) expressing all early proteins is markedly more efficient at
initiating origin replication than the LT cDNA alone (Fig. 8, lane
7), consistent with an accessory role for sT in LT-mediated DNA
replication. Unlike virion production, however, coexpression of
hVam6p does not significantly change in vitro MCV origin
replication by TAg (Fig. 8, lane 5) or LT cDNA (Fig. 8, lane 9).
Further, the LT.W209A substitution in either TAg or LT cDNA
does not appreciably affect origin replication efficiency (Fig. 8,
lanes 4, 6, 8 and 10).
Failure to achieve secondary MCV-HF transmission
We used fraction 4 (Fig. 3A), which contains encapsidated MCV
virions to infect a variety of cell types including 293, 293TT,
UISO, A549, BJAB, Raji, BSC40 and PBMC purified from whole
blood with or without polybrene treatment. No cytopathic effect
(CPE) was observed in long-term culture (4 weeks). Immunoblot-
ting and immunofluorescence staining for T antigen and VP1
proteins were not positive for cells exposed to virus (data not
shown). We also did not detect viral transcripts by RT-PCR (not
shown), suggesting no secondary detectable infection occurred.
Co-culture of MCV-HF transfected 293 cells with 293, A549 and
UISO cells separated by 0.2 or 0.45-mm membranes on a transwell
plate also failed to demonstrate secondary virus infection. These
results may be due in part to the limited amount of infectious virus
generated after transfection.
Discussion
We generated a replicating MCV molecular clone that can be
manipulated to assess effects on virus DNA replication and
encapsidation. As previously seen in origin-replication studies [3],
introduction of the MCV350 strain point mutation into the MCV-
HF replication origin abolishes the clone’s ability to replicate. We
also confirm that MCV sT protein expression together with LT
expression is required for optimal MCV replication, a feature of
Figure 3. Fractionation of viral capsid protein VP1 by OptiprepTM density gradient ultracentrifugation. (A) Twelve fractions were
collected from highest to lowest density, and analyzed by immunoblotting with CM9B2 antibody to detect VP1 capsid protein. Assembled 45 kDa
VP1 protein is isolated in fraction 4. Unassembled, free VP1 protein is present in Fractions 9 and 10. The positive control (+) is virus-like particle (VLP)
prepared from 293TT cells by MCV VP1 and VP2 transfection. (B) Typical 40 nm diameter icosahedral Merkel cell polyomavirus particles present in
fraction 4 (upper panel) and VP1/VP2-containing MCV virus-like particles for comparison (bottom panel). (C) Nuclease-resistant MCV DNA in various
gradient fractions quantitated by real time PCR. Highest levels of encapsidated DNA are present in fraction 4, corresponding to the fraction having
MCV virions. (D) Time-course for MCV virion production after transfection of 1 mg replication competent (MCV-HF) or incompetent (MCV-Rep2)
genomes into 293 cells was determined on lysed cells by quantitative PCR after nuclease treatment. Genome replication and packaging of MCV-HF is
evident by day 3.
doi:10.1371/journal.pone.0022468.g003
Merkel Cell Polyomavirus Molecular Clone
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viral genome replication that MCV shares with the human JC
polyomavirus [26].
Fully-encapsidated MCV virions from MCV-HF were isolated
in fraction 4 at 1.24 g/ml on iodixanol (OptiprepTM) gradients.
Evidence that these are fully-encapsidated viruses include isolation
of nuclease-protected DNA and ultra-high molecular weight
aggregates of VP1 protein specific to this fraction. In the 1970s,
hyperosmolar CsCl isopycnic gradients were used to isolate
polyomaviruses having higher apparent buoyant densities (e.g.,
1.34 g/ml [27]). It is now well-established that hyperosmolar CsCl
gradients overestimate the densities of large macromolecular
structures, such as viruses, since CsCl gradients dehydrate virions,
replacing water with heavy salts, which reduces viability and
artifactually increases the buoyant density. JC virus has a buoyant
density of 1.20 g/ml on linear sucrose gradients and 1.35 g/ml in
CsCl gradients [28]. Similarly, goose hemorrhagic polyomavirus
virion has a 1.20 g/ml density in sucrose and an apparent 1.34–
1.35 g/ml density with CsCl gradients [29,30]. MCV DNA has
been isolated from skin at 1.22 g/ml density using iodixanol
gradients, which is in agreement with our findings [22]. The
encapsidated MCV we identify in fraction 4 using uranyl acetate
negative staining have the same size (,40 nm) as similarly
prepared MCV VLP but are smaller than MCV VLP (55–
58 nm) visualized using phosphotungstic acid staining [7].
Figure 4. MCV genome replication. Southern blot (right panel) for MCV for MCV-HF (lane 1), MCV-Rep2 (lane 2) and MCV-hVam6p2 (lane 3)
viruses four days after transfection of 1 mg circular genomic DNA into 293 cells. Panel on left shows the ethidium bromide-stained gel prior to transfer
indicating equal DNA loading. Bands for the full-length 5.4 kb MCV genome are present as DpnI-resistant bands in MCV-HF and MCV-hVam6p2
viruses (lanes 1 and 3) but not in the replication deficient MCV-Rep2 virus (lane 2). The replication efficiency was measured by the ratio between the
DpnI-resistant 5.4 kb band and the DpnI-sensitive band. The MCV-hVam6p2 virus generates ,2-fold more full length genome compared to wild-type
MCV-HF virus. Replicated viral DNAs also show the presence of extensive subgenomic fragments.
doi:10.1371/journal.pone.0022468.g004
Merkel Cell Polyomavirus Molecular Clone
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MCV, like other polyomaviruses, has a strictly regulated order
of viral gene expression that leads to encapsidation of the viral
genome. MCV LT and 57kT proteins are expressed early after
MCV-HF transfection. Subsequently sT and VP1 (and presum-
ably other virion protein components) are detectably expressed,
leading to generation of self-assembling viral particles. Our study
reveals an unexpected and interesting complexity for MCV gene
expression. MCV LT, sT and 57kT are generated from
alternatively-spliced, overlapping genes driven by the same early
promoter. MCV-Rep2 expression for LT is initially identical to
MCV-HF, indicating that the early promoter is intact, but other
early proteins are diminished (57kT) or absent (sT) suggesting the
possibility that viral DNA replication also regulates early TAg
splicing. Late VP1 protein expression also is not detected using the
MCV-Rep2 genome indicating that it is likely the early-to-late
promoter switch also depends on viral DNA replication. This is
similar to mouse polyomavirus, a close relative to MCV in the
murine polyomavirus clade [5]. Well-established late lytic
expression and packaging cascades for other viruses, such as
herpesviruses, are also dependent on active viral DNA replication
[31]. Although our results are consistent with DNA replication-
dependent viral transcription, MCV-Rep2 is mutated with a single
pentamer sequence (PS) 7/8 substitution in the MCV origin and
so we cannot exclude the possibility that this point mutation also
affects late promoter activity in addition to genome replication.
Additional studies are needed to determine if DNA replication also
regulates MCV splicing patterns.
One key factor determining MCV-HF virion production is the
abundance of sT protein, which our data suggests is in turn
increased in a positive feedback loop during MCV replication.
When sT is coexpressed with the transfected MCV-HF genome,
there is 5–6 fold increased virus production. For mouse
polyomavirus, sT can signal to AP-1 and PEA3 factors to promote
viral replication and late gene expression [32]. Based on SV40
Figure 5. Quantitative PCR for MCV virion production for MCV-HF, MCV-Rep2 and MCV-hVam6p2 viruses. One microgram MCV clone
DNAs were transfected into 293 cells stably transduced to express MCV sT or LT proteins (not shown). DNA was extracted and treated with benzonase
and RNase to discriminate packaged viral DNA. The nuclease-resistant MCV genome was precipitated and measured by quantitative PCR after
proteinase K treatment. Cellular sT expression increases virion production for both MCV-HF and MCV-hVam6p2 viruses. Comparison of MCV-HF and
MCV-hVam6p2 shows that loss of the hVam6p binding site also increases virus production. Coexpression of sT and mutation of the hVam6p binding
site in the MCV genome are additive in virion production compared to MCV-HF without sT coexpression.
doi:10.1371/journal.pone.0022468.g005
Table 1. Optimization of MCV production in various cell lines
and effect of co-expression of viral proteins.
Cell lines Co-transfected MCV plasmid(s) Production level*
293 None1 " ++
Large T antigen1 " ++
Small T antigen1 " +++
UISO None1 +
Genomic T antigen1 +
VP1 and VP21 +
293TT None1 +/2
Genomic T antigen1 +
VP1 and VP21 +/2
3T3 None1 +/2
Genomic T antigen1 +
COS7 None1 +/2
Genomic T antigen1 +
*Note: Relative expression was determined in individual experiments by PCR(1) ,
MCV protein expression ("), or both.
doi:10.1371/journal.pone.0022468.t001
Merkel Cell Polyomavirus Molecular Clone
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studies, the most prominent role of sT involves inhibition or
retargeting of substrates for the major cellular phosphatase, PP2A
[33]. We previously identified MCV sT as an important accessory
factor for efficient MCV DNA replication [3], but it is unknown
whether this is due to PP2A or 4E-BP1 targeting, or due to
targeting of our other cellular factors [15]. The Southern blot in
Figure 4 reveals that MCV DNA replication is sparse and most of
the replicated DNA is fragmented. This suggests that MCV
genome replication, at least under conditions of plasmid
transfection, is inefficient and small increases in successful MCV
genome replication may have a large impact on virion replication
and encapsidation. Whether the same is true during natural
infection will only be determined through development of a
successful MCV transmission system.
Our findings that hVam6p inhibits MCV production are
unexpected and, to a degree, paradoxical. MCV LT retains a
conserved hVam6p-binding domain that represses virion produc-
tion. Other polyomaviruses also encode gene sequences that
repress viral replication [34], which might reflect the need for
these small DNA viruses to suppress virus replication to sustain a
chronic, persistent infection without virion production (e.g.,
latency). Although the effects of hVam6p on MCV replication
are clear, the mechanism by which hVam6p suppresses replication
is not. Our origin replication studies in the presence and absence
of hVam6p overexpression, together with LT.W209A mutations
in LT coding region, show no direct effect of hVam6p on initiation
of viral DNA replication. Additional studies are also needed to
investigate this effect, however, since Southern blotting reveals
amplified viral DNA replication for MCV-hVam6p2 virus
compared to MCV-HF, suggesting hVam6p might be inhibitory
to viral DNA replication in the context of the full viral genome.
It is noteworthy that overexpression of this vacuolar sorting
protein has a profound antiviral effect on MCV replication.
hVam6p possesses citron and clathrin homology domains, the
Figure 6. Comparison of viral packaging for MCV-HF, MCV-Rep2 and MCV-hVam6p2 viruses. OptiprepTM density gradient fractions from
wild type (MCV-HF) and mutant viruses (MCV-Rep2, MCV-hVam6p2) generated from transfected 293 cells were used for Western blotting. Dilutions
of MCV virus-like particles (VLP) provide a marker for the relative abundance of VP1 protein in each fraction. Assembled MCV-hVam6p2 virus VP1
expression is ,10 fold increased in fraction 4 compared to MCV-HF.
doi:10.1371/journal.pone.0022468.g006
Figure 7. Effect of hVam6p coexpression on MCV virion production. 293 cells cotransfected with hVam6p and MCV genomes at day 4 as
measured by nuclease-resistant DNA by quantitative PCR. Circularized viral plasmids (1 mg) together with varying amounts of hVam6p expression
plasmid were simultaneously transfected during this experiment.
doi:10.1371/journal.pone.0022468.g007
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latter being involved in MCV LT binding [24], that are important
to its functions in the HOPS-CORVET complex as an accessory
factor for endosomal fusion [35]. In yeast, the hVam6p homolog
also has been reported to act as a guanine nucleotide exchange
factor for Gtr1 that contributes to TORC1 activation [36]. An
isoform of hVam6p, TRAP-1-like protein (TLP) regulates the
balance between Smad2 and Smad3 in TGF-ß signaling [37].
Previous studies did not find either mTOR activation or TGF-ß
signaling, however, to be appreciably altered by MCV LT
expression [24]. In our current study, even low levels of hVam6p
transfection reduce MCV-HF virus production to levels similar to
the replication-deficient clone demonstrating that it is a potent
factor restricting MCV replication. For the MCV-hVam6p2 virus,
hVam6p inhibits replication in a dose-dependent manner, which
Figure 8. Effects of hVam6p on in vitro MCV origin replication. 293 cells were transfected with plasmids containing MCV origin and equal
amounts of either wild type of genomic T antigen (TAg), LT cDNA, or the corresponding constructs containing the hVam6p-binding site mutations
(TAg.W209A and LT.W209A). Origin replication was assessed through Southern blotting by comparing the ratio of DpnI-resistant (replicated) to DpnI-
sensitive (unreplicated) DNA. For each condition, replication in the absence or presence of simultaneously cotransfected hVam6p expression plasmid
was determined. Expression of the genomic TAg containing both sT and LT showed increased replication of the MCV origin compared to the LT cDNA
regardless of hVam6p coexpression. Neither mutation of the hVam6p binding site on LT nor coexpression of exogenous hVam6p significantly altered
MCV origin replication.
doi:10.1371/journal.pone.0022468.g008
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may be due to either the W209A substitution incompletely
disabling the hVam6p-binding site or hVam6p acting in other
steps of MCV replication beyond those depending on LT. If
hVam6p plays a role in inhibiting egress of MCV, this might
represent a novel component of innate immunity. Tetherin, for
example, is a recently-discovered innate immune component that
prevents enveloped viral budding from cells [38]. Detailed analysis
of hVam6p’s role in antiviral responses is beyond our current
study but development of a replicating MCV clone that can be
genetically manipulated provides a critical reagent for use in these
follow-on investigations.
Secondary MCV transmission was not detected in our study
suggesting that MCV may have a tissue tropism that is not easily
modeled in undifferentiated tissue culture. MCV resembles some
other small DNA viruses in this way, such as JCV as well as other
human tumor viruses including human papillomaviruses (HPV),
hepatitis B and C viruses and KSHV. Poor MCV transmissibility
could be due in part to low virus yields from our molecular clone
system that might be improved with other MCV strains or cell
culture settings. Cloning MCV-HF, however, provides a useful
tool for these testing conditions to optimize virus yield that may
ultimately allow a laboratory transmission model.
Materials and Methods
Cell lines and clinical samples
293 cell line (ATCC), 293FT (Invitrogen Inc.), 293TT [7],
NIH3T3 (ATCC), A549 (ATCC), COS7 (ATCC) and BSC40
(ATCC) were maintained in DMEM medium supplemented with
10% FBS, penicillin and streptomycin (pen/strep). MKL-1 [13],
UISO [13], BJAB (ATCC), Raji (ATCC) and peripheral blood
mononuclear cell (PBMC) were cultured in RPMI 1640 medium
with 10% FBS and pen/strep. MCC clinical specimens (MCC350,
MCC337, MCC339, MCC344, MCC345, MCC347, MCC349
and MCC352) and PBMC sample have been described [1].
Clinical samples were collected under University of Pittsburgh
Institutional Review Board (IRB) guidelines for study of human
tissues.
Characterization of MCV genomes and construct
consensus MCV genomes
MCV genomes in MCC cases were directly sequenced with 13
pairs of contig primer sets as previously described [1]. Long PCR
was performed to amplify the whole genome in a MCV positive
PBMC sample with two primer sets (contig.1f-8r and contig.9f-1r).
The consensus genome (MCV-HF) was generated from 6 tumor-
type MCV genomes and 1 wild-type MCV genome using
MacVector program (MacVector Inc.). The whole genome was
synthesized by the DNA 2.0 Inc (Menlo Park, CA) and cloned into
a Kanamycin selectable vector. The consensus MCV genome was
linearized at a BsrFI restriction site (RCCGGY) in the VP region.
A replication-defective MCV genome (MCV-Rep2) was muta-
genesized from consensus MCV-HF with 59-GAA AAA AAA
GAG AGA GGA CTC TGA GGC TTA AGA G-39 and 59-CTC
TTA AGC CTC AGA GTC CTC TCT CTT TTT TTT C-39
primers, using the QuikChange Lightning Site-Directed Muta-
genesis kit (Stratagene). MCV-hVam6p2 was generated with the
primer set (W209A.S: 59-GAA CGG ATG GCA CCG CGG
AGG ATC TCT TCT GC-39, W209A.AS: 59- GCA GAA GAG
ATC CTC CGC GGT GCC ATC CGT TC-39) to eliminate the
hVam6p binding to T antigen [24]. Plasmids containing MCV-
HF, MCV-Rep2 or MCV-hVam6p2 were propagated in E. coli
JM109 and purified using the Qiagen maxiprep kit (Valencia, CA).
Linear MCV was digested out with BsrFI and re-ligated into
circular form under low concentration of T4 ligase (1 U/ml, New
England Biolabs) overnight at 16uC. Circular DNA was further
digested with AvaI to linearize non-MCV DNA, and treated with
Plasmid-SafeTM Exonuclease (Epicentre, Madison, WI) to isolate
circular MCV genomes. All three genomes were sequenced
confirmed.
Nuclease-protection assay
Cells transfected with MCV-HF or MCV-Rep2 or MCV-
hVam6p2 were collected and lysed with 3 freeze-thaw cycles in
DPBS-Mg2+ buffer. After centrifugation, supernatants were
treated with 250 units of benzonase (Promega) and 5 units of
RNase A (Ambion) at 37uC for 4 hrs. EDTA was then added to
inactivate nuclease. Proteinase K was used to digest capsid
proteins at 56uC for 1 hr. The capsid-protected MCV DNA was
prepared by phenol-chloroform extraction and dissolved in 50 ml
TE buffer. One microliter of DNA was used for PCR
quantification with VP2 primers and TaqMan probe as previously
described [39].
Immunoblotting
293 cells and stably infected 293 cells lines with LT or sT
lentiviral vector (293-LT or 293-sT) were seeded in 6-well plates
and transfected with 1 mg circularized MCV genomes using
Lipofectamine 2000 (Invitrogen). Radio immunoprecipitation
assay buffer (RIPA) was used to lyse cells. Monoclonal antibody
CM2B4 [39] was used to examine LT antigen and 57kT antigen
expression at 1:2000 dilution. Monoclonal antibody CM8E6 [17]
was used to detect sT antigen expression at a dilution of 1:250.
Late gene expression of VP1 was examined with monoclonal
antibody CM9B2 at dilution of 1:2000. The CM9B2 antibody
(IgG2b isotype) was generated by immunizing mice with KLH-
derivatized (DKGKAPLKGPQKASQKES) peptide from MCV
VP1 using standard methods (Epitope Recognition Immunor-
eagent Core Facility, University of Alabama) and tested for
reactivity to the MCV VP1 protein [7]. Tubulin (Sigma) was used
to quantitate sample input at dilution of 1:2000.
Lentivirus production and infection
293FT cells (Invitrogen) were transfected with lentiviral
construct containing MCV LT or sT antigen together with
packaging plasmids, psPAX2 and pMD2.G (Addgene) in 100 mm
dish by Lipofectamine 2000 (Invitrogen). 293 cells were infected
with lentivirus in the presence of 1 mg/ml polybrene. At day 3
after infection, puromycin (3 mg/ml) was added, and infected cells
were selected in bulk for 7 days for stably expression of MCV LT
and sT antigen. Expression was confirmed by immunoblotting.
MCV origin replication
For MCV origin replication assay, 293 cells were transfected
with a plasmid containing MCV origin (Ori339(589)) [3] together
with wild type (genomic T (TAg), LT) or mutant type
(TAg.W209A, LT.W209A) of T antigens as well as hVam6p gene
[25]. These cells were harvested at day 2 after transfection. Low
molecular weight DNA was extracted with modified Hirt-
extraction and Southern blot analysis was performed by method
previously described [3] with a MCV origin probe (5,074–65 nt)
amplified by PCR with primers: 59-CTC GAG AGC AAT TTC
ACC AAT ATT GGC C-39 and 59- GAT ATC TAA GCC TCT
TAA GCC TCA GAG TCC-39. To measure MCV clone
replication, 2.5 mg of extracted DNA was digested overnight with
5 units of DpnI and BamHI and subjected to Southern blotting.
Same MCV origin probe was used to measure replication
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efficiency. The blot was analyzed by using a PhosphorImager
(Typhoon 9400, GE Healthcare) and ImageJ software (National
Institute of Health, USA).
Virion purification and cell infection
At day 4 after post-transfection, cells were harvested and
matured overnight with benzonase, RNase A and Plasmid-safeTM
nuclease as previously described [7]. Cell lysate was separated on a
27-33-39% Optiprep (Sigma, St. Louis, MO) gradient after
ultracentrifugation for 3.5 hrs at 234,000 g. Fractions were
collected after puncturing the bottom of ultracentrifuge tube using
a 25-G needle and stored at 280uC. Viral particles were stained
with 1% uranyl acetate negative staining and observed on JEOL
JEM-1011 (Tokyo, Japan) electron microscope at 80 kV and
compared to self-assembling VP1-VP2 MCV virus-like particles
generated as previously described [7]. In MCV infection assays,
various cells (293, 293TT, UISO, A549, BJAB, Raji, BSC40 and
PBMC purified from whole blood) were cultured with 4 ml
ultracentrifuged fractions containing MCV virions together with
or without 1 mg/ml polybrene (Sigma) treatment. For transwell
experiments, 6-well transwell plates were used (Corning, New
York, USA) with a 0.2 or 0.45-mm pore size polycarbonate
membrane. Transfected 293 cells with MCV-HF genomes were
labeled with intracellular fluorescent dye 5- (and -6)-carboxyfluor-
escein diacetate succinimidyl ester (CFSE) to monitor any cell
contamination in transwell experiments. 293, A549 and UISO
were seeded in the lower chamber to co-culture with transfected
293 cells for 6 days.
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